X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

RLMD

Closed

Relmada Therapeutics Inc

0.6161
+0.0158 (+2.63%)
Last Update: 01 Jul 2025 23:13:00
Yesterday: 0.6003
Day's Range: 0.6161 - 0.667899
Send
When Written:
 
2.28
Relmada Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company's lead drug candidate is d-Methadone, which is being developed as a potential treatment for neuropathic pain and other CNS disorders.

Relmada Therapeutics was founded in 2004 and is headquartered in New York City. The company's research and development efforts are focused on identifying and developing new drug candidates that target specific receptors in the CNS.

In addition to d-Methadone, Relmada Therapeutics has a pipeline of other drug candidates in various stages of development, including REL-1017, which is being developed as a potential treatment for depression and other CNS disorders.

Relmada Therapeutics is publicly traded on the NASDAQ stock exchange under the ticker symbol "RLMD".

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X